A whale repurchased 800 BTC after a year's hiatus, worth $84.87 million.
according to on-chain analyst Yu Jin's monitoring, a whale who sold BTC in November last year and has not made any transactions since then, has started buying again today after a year, purchasing 800 BTC ($84.87 million) at a price of $106,060. He made a total profit of $120 million through 3 BTC price swings between 2022-2024, and today marks his 4th purchase.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Solana News Today: "While Zcash Surges, Ghostware Quietly Advances Scalable Solutions on Solana"
- Privacy-focused crypto tokens like $GHOST and $EYE gain traction amid market volatility, driven by demand for verifiable infrastructure and scalable solutions. - A major whale's $16.7M investment in $GHOST and GhostwareOS's Solana-based privacy modules highlight growing institutional confidence in the ecosystem. - Solana ETFs attract $421M in inflows, contrasting broader crypto outflows, while $EYE's renewable energy-AI hybrid model offers tangible asset-backed returns. - Zcash's 1,000% surge underscores

BNB News Today: Apriori Suffers 80% Token Loss, Raising Concerns Over Crypto Airdrop Security and Trust
- Apriori's BNB Chain airdrop lost 80% of tokens to a Sybil group via 5,800 interconnected wallets funded by 13 addresses. - The attack exploited pre-announcement timing and empty wallets, undermining trust in the project's fair distribution claims. - APR token price fell over 60% post-incident, mirroring similar Sybil exploits at MYX Finance and zkSync that siphoned millions. - Experts demand stronger anti-fraud measures like multi-factor checks as BNB Chain faces scrutiny over recent security lapses.

Pfizer Files Lawsuit Against Novo: Alleges Competitor Engaged in Antitrust Scheme to Dominate Obesity Market
- Pfizer sues Novo Nordisk and Metsera in Delaware courts, alleging anticompetitive tactics to block its $7.2B obesity drug acquisition. - Novo's $8.5B superior bid for Metsera's GLP-1 pipeline—valued at $5B peak sales—triggers legal claims over regulatory bypass and contract violations. - Pfizer leverages early FTC approval for its deal, seeking court orders to force a November 13 shareholder vote amid patent expiration threats. - The dispute highlights $150B obesity market stakes, with Novo defending its

Hidden Leverage and External Party Risks Lead to XUSD Downfall
- Stream Finance's XUSD stablecoin collapsed to $0.30, freezing $160M in user funds after a $93M loss linked to an external fund manager. - The crisis followed a $100M exploit at Balancer Protocol, amplifying DeFi market anxiety and triggering rapid fund withdrawals. - Stream's high-leverage model and hidden $520M TVL vs. $160M actual deposits raised red flags about risky third-party fund usage. - XUSD's collapse exposed DeFi vulnerabilities, reigniting debates on third-party risks and urging audits for pr

